Sigma Planning Corp Sells 30,510 Shares of uniQure (NASDAQ:QURE)

Sigma Planning Corp reduced its stake in shares of uniQure (NASDAQ:QURE) by 51.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,745 shares of the biotechnology company’s stock after selling 30,510 shares during the period. Sigma Planning Corp owned 0.06% of uniQure worth $195,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. 683 Capital Management LLC raised its stake in shares of uniQure by 21.6% in the 3rd quarter. 683 Capital Management LLC now owns 1,575,000 shares of the biotechnology company’s stock valued at $10,568,000 after acquiring an additional 280,000 shares in the last quarter. Barclays PLC lifted its stake in shares of uniQure by 527.8% in the third quarter. Barclays PLC now owns 989,562 shares of the biotechnology company’s stock worth $6,641,000 after buying an additional 831,929 shares during the last quarter. Citigroup Inc. boosted its holdings in shares of uniQure by 667.9% during the 3rd quarter. Citigroup Inc. now owns 766,521 shares of the biotechnology company’s stock worth $5,143,000 after buying an additional 666,696 shares during the period. Algert Global LLC grew its stake in uniQure by 237.6% in the 3rd quarter. Algert Global LLC now owns 414,241 shares of the biotechnology company’s stock valued at $2,780,000 after buying an additional 291,541 shares during the last quarter. Finally, abrdn plc bought a new position in uniQure in the 4th quarter worth $2,711,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Insider Activity

In other uniQure news, COO Pierre Caloz sold 9,455 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $6.47, for a total transaction of $61,173.85. Following the sale, the chief operating officer now directly owns 85,643 shares of the company’s stock, valued at $554,110.21. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CFO Christian Klemt sold 15,906 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $6.38, for a total value of $101,480.28. Following the completion of the sale, the chief financial officer now owns 116,948 shares of the company’s stock, valued at $746,128.24. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Pierre Caloz sold 9,455 shares of the company’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $6.47, for a total value of $61,173.85. Following the transaction, the chief operating officer now directly owns 85,643 shares in the company, valued at approximately $554,110.21. The disclosure for this sale can be found here. In the last quarter, insiders have sold 53,265 shares of company stock worth $339,845. Corporate insiders own 4.05% of the company’s stock.

uniQure Trading Down 3.1 %

Shares of QURE opened at $4.39 on Tuesday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 8.68 and a current ratio of 8.85. The company has a 50-day moving average price of $5.24 and a two-hundred day moving average price of $5.96. uniQure has a 12 month low of $4.35 and a 12 month high of $22.48.

uniQure (NASDAQ:QURE) last posted its earnings results on Wednesday, February 28th. The biotechnology company reported ($1.53) EPS for the quarter, topping the consensus estimate of ($1.54) by $0.01. The business had revenue of $6.69 million during the quarter, compared to the consensus estimate of $3.20 million. uniQure had a negative return on equity of 99.31% and a negative net margin of 1,947.09%. On average, research analysts predict that uniQure will post -4.49 EPS for the current year.

Analysts Set New Price Targets

QURE has been the topic of a number of recent analyst reports. The Goldman Sachs Group lowered uniQure from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $63.00 to $8.00 in a research note on Thursday, February 29th. Royal Bank of Canada restated an “outperform” rating and issued a $28.00 price objective on shares of uniQure in a research note on Tuesday, January 16th. StockNews.com raised shares of uniQure to a “sell” rating in a report on Friday, March 1st. HC Wainwright dropped their price objective on shares of uniQure from $30.00 to $25.00 and set a “buy” rating on the stock in a report on Friday, March 1st. Finally, Mizuho reduced their target price on shares of uniQure from $10.00 to $7.00 and set a “neutral” rating for the company in a research note on Monday, March 4th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $32.00.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.